Cargando…

Impact of lenvatinib on renal function compared to sorafenib for unresectable hepatocellular carcinoma

Anti-VEGF drugs, such as tyrosine kinase inhibitors, play an important role in systemic therapy for unresectable hepatocellular carcinoma (uHCC). We examined the effects of sorafenib and lenvatinib on proteinuria and renal function. Patients who were administered sorafenib (n = 85) or lenvatinib (n ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sasaki, Ryu, Fukushima, Masanori, Haraguchi, Masafumi, Honda, Takuya, Miuma, Satoshi, Miyaaki, Hisamitsu, Nakao, Kazuhiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	4500
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276219/ https://www.ncbi.nlm.nih.gov/pubmed/35583540 http://dx.doi.org/10.1097/MD.0000000000029289

Ejemplares similares

Shunt occlusion prior to lenvatinib administration prevents hepatic encephalopathy and hyperammonemia
por: Kuwahara, Ai, et al.
Publicado: (2020)

Evaluating the Role of Hepatobiliary Phase of Gadoxetic Acid-Enhanced Magnetic Resonance Imaging in Predicting Treatment Impact of Lenvatinib and Atezolizumab plus Bevacizumab on Unresectable Hepatocellular Carcinoma
por: Sasaki, Ryu, et al.
Publicado: (2022)

The impact of single-nucleotide polymorphisms on liver stiffness and controlled attenuation parameter in patients treated with direct-acting antiviral drugs for hepatitis C infection
por: Matsumoto, Kosuke, et al.
Publicado: (2022)

Peripheral lymphocyte fluctuation as an indicator of severe immune‐related adverse events in patients treated with immune checkpoint inhibitors
por: Haraguchi, Masafumi, et al.
Publicado: (2023)

Hypoglycemia measured by flash glucose monitoring system predicts liver-related events in chronic liver disease patients
por: Sasaki, Ryu, et al.
Publicado: (2023)

The Long-term Efficacy of Sodium Glucose Co-transporter 2 Inhibitor in Patients with Non-alcoholic Fatty Liver Disease
por: Yamashima, Mio, et al.
Publicado: (2019)

Response to Lenvatinib Is Associated with Optimal RelativeDose Intensity in Hepatocellular Carcinoma: Experience in Clinical Settings
por: Sasaki, Ryu, et al.
Publicado: (2019)

Blood carnitine profiling on tandem mass spectrometry in liver cirrhotic patients
por: Miyaaki, Hisamitsu, et al.
Publicado: (2020)

Influence of Interferon-free Direct-acting Antiviral Therapy on Primary Hepatocellular Carcinoma Recurrence: A Landmark Time Analysis and Time-dependent Extended Cox Proportional Hazards Model Analysis
por: Miuma, Satoshi, et al.
Publicado: (2020)

Treatment of Hepatitis C Virus Infection with Direct-acting Antiviral Agents Elevates the Serum Small-dense Low-density Lipoprotein Cholesterol Level
por: Hino, Naoyuki, et al.
Publicado: (2021)

Intractable Hepatic Encephalopathy with a Large Portosystemic Shunt Successfully Treated Using Shunt-preserving Disconnection of the Portal and Systemic Circulation
por: Haraguchi, Masafumi, et al.
Publicado: (2020)

Most Cases of Cryptogenic Cirrhosis May Be Nonobese Nonalcoholic Steatohepatitis - Risk Factors of Liver Steatosis After Liver Transplantation for Cryptogenic Cirrhosis: A Retrospective Study
por: Fukushima, Masanori, et al.
Publicado: (2022)

Extracellular vesicles from senescent hepatic stellate cells promote cell viability of hepatoma cells through increasing EGF secretion from differentiated THP-1 cells
por: Miyazoe, Yuri, et al.
Publicado: (2020)

Initial and advanced endoscopic findings of monomorphic epitheliotropic intestinal T‐cell lymphoma in the duodenum: A case report
por: Fukushima, Masanori, et al.
Publicado: (2022)

Inferior Vena Cava Anomalies with Portal Vein System Continuation Presenting as Portal Hypertension with a Long-term Follow-up
por: Fukushima, Masanori, et al.
Publicado: (2020)

Comparison of the novel Franseen needle versus the fine‐needle aspiration needle in endoscopic ultrasound‐guided tissue acquisition for cancer gene panel testing: A propensity score‐matching analysis
por: Mori, Tomotaka, et al.
Publicado: (2023)

Geranylgeranylacetone attenuates fibrogenic activity and induces apoptosis in cultured human hepatic stellate cells and reduces liver fibrosis in carbon tetrachloride-treated mice
por: Senoo, Takemasa, et al.
Publicado: (2018)

Comparative study of the effect of neuromuscular electrical stimulation and oral administration of branched-chain amino acid on preventing sarcopenia in patients after living-donor liver transplantation: study protocol for an open-label randomized controlled trial
por: Haraguchi, Masafumi, et al.
Publicado: (2021)

Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab
por: Yano, Shigeki, et al.
Publicado: (2021)

Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib
por: Chen, Yen-Yang, et al.
Publicado: (2020)

Incidence and computed tomography findings of lenvatinib-induced pancreatobiliary inflammation: A single-center, retrospective study
por: Kurokawa, Ryo, et al.
Publicado: (2021)

Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy
por: Burgio, Valentina, et al.
Publicado: (2021)

Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis
por: Zhao, Shu, et al.
Publicado: (2022)

Fully covered metallic stents for anastomotic biliary strictures after living donor liver transplantation
por: Komatsu, Naohiro, et al.
Publicado: (2023)

Sorafenib as second‐line treatment option after failure of lenvatinib in patients with unresectable hepatocellular carcinoma
por: Tomonari, Tetsu, et al.
Publicado: (2020)

TACE plus percutaneous chemotherapy-lipiodol treatment of unresectable pedunculated hepatocellular carcinoma
por: Huang, Dexiao, et al.
Publicado: (2017)

Hepatitis C Virus Infection Increases c-Jun N-Terminal Kinase (JNK) Phosphorylation and Accentuates Hepatocyte Lipoapoptosis
por: Takaki, Hiroko, et al.
Publicado: (2017)

Sorafenib prescribed by gastroenterologists and hepatologists for hepatocellular carcinoma: A retrospective, multi-institutional cohort study
por: Kaplan, David E., et al.
Publicado: (2018)

Combination Therapy of Radiofrequency Ablation and Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Retrospective Study
por: Tang, Chengwu, et al.
Publicado: (2016)

HAIC versus TACE for patients with unresectable hepatocellular carcinoma: A systematic review and meta-analysis
por: Liu, Junguo, et al.
Publicado: (2022)

Clinical usefulness of geriatric assessment in elderly patients with unresectable hepatocellular carcinoma receiving sorafenib or lenvatinib therapy
por: Sekiguchi, Shuhei, et al.
Publicado: (2022)

Real-World Effectiveness of Sorafenib versus Lenvatinib Combined with PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma
por: Chiang, Hsueh-Chien, et al.
Publicado: (2023)

Clinical efficacy and safety of atezolizumab plus bevacizumab versus lenvatinib in the treatment of advanced hepatocellular carcinoma: A systematic review and meta-analysis
por: Du, Sihao, et al.
Publicado: (2023)

Prediction of Liver Prognosis from Pre-Transplant Renal Function Adjusted by Diuretics and Urinary Abnormalities in Adult-to-Adult Living Donor Liver Transplantation
por: Kitamura, Mineaki, et al.
Publicado: (2020)

Determinants of Survival After Sorafenib Failure in Patients With BCLC-C Hepatocellular Carcinoma in Real-World Practice
por: Lee, I-Cheng, et al.
Publicado: (2015)

Combination treatment of transcatheter arterial chemoembolization, intensity-modulated radiotherapy, and sorafenib for hepatocellular carcinoma with macrovascular invasion
por: Yang, Dan, et al.
Publicado: (2023)

Hepatic arterial infusion chemotherapy vs transcatheter arterial embolization for patients with huge unresectable hepatocellular carcinoma
por: Tsai, Wei-Lun, et al.
Publicado: (2020)

Elevated Fasting Plasma Glucose before Liver Transplantation is Associated with Lower Post-Transplant Survival
por: Katsura, Emi, et al.
Publicado: (2016)

Sorafenib treatment on Chinese patients with advanced hepatocellular carcinoma: A study on prognostic factors of the viral and tumor status
por: Lee, Shou-Wu, et al.
Publicado: (2019)

Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan
por: Kobayashi, Masahiro, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_17enmn5q0rqrm53augiotd4bn5